Cancer Therapies

Cancer Therapies

Global Cancer Therapies Market to Reach $254.4 Billion by 2027

In the changed post COVID-19 business landscape, the global market for Cancer Therapies estimated at US$140.3 Billion in the year 2020, is projected to reach a revised size of US$254.4 Billion by 2027, growing at a CAGR of 8.9% over the analysis period 2020-2027. Chemotherapy, one of the segments analyzed in the report, is projected to record a 8.3% CAGR and reach US$74.7 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Targeted Therapy segment is readjusted to a revised 9.1% CAGR for the next 7-year period.

The U.S. Market is Estimated at $54.2 Billion, While China is Forecast to Grow at 10.3% CAGR

The Cancer Therapies market in the U.S. is estimated at US$54.2 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$20.3 Billion by the year 2027 trailing a CAGR of 10.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.4% and 8.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 10.2% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$14.7 Billion by the year 2027.

Immunotherapy Segment to Record 9.7% CAGR

In the global Immunotherapy segment, USA, Canada, Japan, China and Europe will drive the 9.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$29.9 Billion in the year 2020 will reach a projected size of US$57.6 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Latin America will expand at a 9.6% CAGR through the analysis period.

Select Competitors (Total 80 Featured) -

  • AbbVie, Inc.
  • Amgen, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca Plc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Glaxosmithkline Plc
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer, Inc.
  • Takeda Pharmaceutical Company Limited.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Cancer Therapies: An Outlook
Chemotherapy & Targeted Therapy Lead the Global Cancer Therapies Market
By Cancer Type
USA Leads the Cancer Therapies Market
Biotherapies to Drive Growth
Rise in Cancer Incidence & Access to Modern Therapeutics Foster Growth
Total Number of New Cancer Cases by Type: 2018
Total Number of Cancer Deaths by Type: 2018
Cancer Incidence by Region: 2018
Cancer Mortality by Region: 2018
Age-Standardized Incidence and Mortality Rates of All Cancers (per 100000 Population) by Region: 2018
Cancer Research Spending Continues to Witness Growth
Number of FDA-Approved Cancer Drugs: 2010-2018
Select Cancer Drug Approvals in 2019
Select Cancer Drug Approvals in 2018
Cancer Drug Pipeline to Change the Pharma Landscape
Increasing Share of Cancer Drugs as % Of Total Pharma Drug Pipeline: 2010-2019
Cancer Therapies – Global Key Competitors Percentage Market Share in 2022 (E)
Select Leading Cancer Drugs Worldwide by Sales: 2018
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS
AbbVie, Inc. (USA)
Amgen, Inc. (USA)
Astellas Pharma, Inc. (Japan)
AstraZeneca Plc. (UK)
Bayer AG (Germany)
Bristol-Myers Squibb Company (USA)
Select Late Stage Compounds in Bristol-Myers Squibb Company’s Oncology Pipeline (As of 2019)
Celgene Corporation (USA)
Eli Lilly and Company (USA)
F. Hoffmann-La Roche Ltd. (Switzerland)
Glaxosmithkline Plc (UK)
Johnson & Johnson Services, Inc. (USA)
Merck KGaA (Germany)
Novartis AG (Switzerland)
Pfizer, Inc. (USA)
Takeda Pharmaceutical Company Limited (Japan)
3. MARKET TRENDS & DRIVERS
Industry Focuses on New Approaches to Treat Cancer
Recent Advancements in Cancer Drug Discovery
A New Immunotherapy Technique that Improves Efficacy and Safety of Cancer Treatment Developed by an Institute for Molecular Engineering Research Team
Lymphoma Therapy Developed by BeiGene Secures US FDA Approval
New Linker Technology for Enhancing Stability of ADCs
Personalized Medicine Gains Importance
Companion Diagnostics Accelerate Role of Personalized Medicine in Cancer Care
North American Companion Diagnostics Market (2019)
European Companion Diagnostics Market by Disease Area (2019)
Innovations in Cancer Drug Delivery: Key Factor in Product Differentiation
Peptoid-based Nanotubes Allow Precise, Targeted Delivery of Cancer Drugs
Combination Therapy: A Double Whammy Success
Patent Expiries of Branded Drugs to Trigger Generic Competition
Patent Expiries of Major Biopharmaceutical Drugs in the US and Europe
Gene Therapy based Approaches Present Potential Weapon for Battle against Cancer
Development of Novel Drug Candidates and Potential Therapies
Non-Viral Gene Therapy to Expedite Cancer Research and Introduction of New Therapies
Rise in Patient Assistance Programs (PAPs)
Top Financial Concerns for Cancer Patients: Ranked In Order of Influence
Oral Oncolytic Abandonment Rate (in %) by Patient Out-of-Pocket Expenses
Growth Drivers and Restraints
Demographics & Lifestyles Raise the Risk of Cancer
Percentage Breakdown of New Cases for All Cancers by Gender (2019)
Percentage Breakdown of New Cases for Colon and Rectum Cancers by Gender (2019)
Percentage Breakdown of New Cases for Lung & Bronchus Cancers by Gender (2019)
Unmet Needs Leave Scope for Further Research and Development
Low Entry Barriers in Cancer Research Encourages Breakthrough Developments
Increasing Investments by National Health Authorities
NCI Funding for Cancer Research (2002, 2008, 2014 and 2020)
Improved Screening, Diagnosis & Patient Survival Rates Trigger Growth
Molecular Imaging of Cancer: Critical in Improving Patient Outcomes
Innovations, Improvements, and Approvals Propel Growth
Select Cancer Drug Approvals (2018 & 2019)
Emerging Challenges in Cancer Drug Development
Drug Failures Deter Prospects of New Therapies
High Prices of Targeted Therapies Act as a Speed Breaker
Estimated Average Monthly Cost of Select Leading Cancer Drugs in the US as of 2016
Cancer Drug Approval Processes Need to Become More Flexible for Encouraging Innovation
Limited Tumor Specificity and Toxicity
Complicated Treatment Protocols: A Major Stumbling Block in Patient Compliance
Reduced Smoking
Global Cigarette Consumption Per Capita by Select Countries for 1970 and 2018
Reimbursement Coverage Remains a Major Challenge
Increase in Multidrug Resistance
Stringent Regulations Delay Market Approval
Challenges Encountered in Clinical Trials
Overview of Cancer Therapy Segments
Immunotherapy: A Promising Segment
Global Cancer Immunotherapy Market by Therapy Type (in %) for 2019
Monoclonal Antibodies for Cancer Treatment
Monoclonal Antibodies in Late-Stage Clinical Trials for Cancer Treatment
Vaccines: A Promising Future Area of Cancer Therapeutics
Approved Therapeutic Cancer Vaccines Worldwide
CAR-T Therapy: An Innovative Therapy Focused on Engineering of Patients’ Immune Cells for Cancer Treatment
UK Researchers New Approach Holds Potential to Boost Immunotherapies
Targeted Therapy: An Overview
Types of Targeted Therapy
Chemotherapy: An Overview
Types of Chemotherapy
Risks Associated with Chemotherapy
Hormone Therapy
Drug Classes in Hormone Therapy
CANCER TYPES, APPROVED AND PIPELINE DRUGS
Prostate Cancer
Global Sales of Leading Prostate Cancer Drugs in US$ Million: 2018
Select General Risk Factors and their Relative Risk Rate in Prostate Cancer
Select FDA Approved Drugs for Palliative Treatment of Advanced Prostate Cancer
Select Drugs that Received Approval for Castration-Resistant Prostate Cancer (CRPC)
Prostate Cancer Phase IV Completed Clinical Trials with Results
Lung Cancer
Age-Standardized Lung Cancer Rates for Select Countries
Age-Standardized Lung Cancer Rates in Men for Select Countries
Age-Standardized Lung Cancer Rates in Women for Select Countries
Select FDA-Approved Non-Small Cell Lung Cancer Drugs
Select Phase IV Completed Clinical Trials with Results: As of Dec, 2019
Select Phase III Completed Clinical Trials with Results: As of December 30, 2019
Breast Cancer
Select FDA Approved Breast Cancer Drugs
Breast Cancer Phase IV Completed Clinical Trials with Results: As of Dec 30, 2019
Breast Cancer Select Phase III Completed Clinical Trials with Results: As of Dec 30, 2019
Renal Cancer
Select FDA-Approved Renal Cell Carcinoma Drugs
Cervical Cancer
Colorectal Cancer
Select FDA-Approved Colorectal Cancer Drugs
Skin Cancer
Pancreatic Cancer
Non-Hodgkin’s Lymphoma
Leukemia
Standard Approved Mode of Therapy for AML by Age Group
Blood Cancer Phase IV Completed Clinical Trials with Results: As of Dec 30, 2019
Blood Cancer Phase III Completed Clinical Trials with Results: As of Dec 30, 2019
Bladder Cancer
Endometrial Cancer
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Cancer Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 2: World Historic Review for Cancer Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 3: World 15-Year Perspective for Cancer Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2021 & 2027
TABLE 4: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 5: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 6: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
TABLE 7: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 8: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 9: World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
TABLE 10: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 11: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 12: World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
TABLE 13: World Recent Past, Current & Future Analysis for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 14: World Historic Review for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 15: World 15-Year Perspective for Hormonal Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
TABLE 16: World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 17: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 18: World 15-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
TABLE 19: World Recent Past, Current & Future Analysis for Blood Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 20: World Historic Review for Blood Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 21: World 15-Year Perspective for Blood Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
TABLE 22: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 23: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 24: World 15-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
TABLE 25: World Recent Past, Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 26: World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 27: World 15-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
TABLE 28: World Recent Past, Current & Future Analysis for Gastrointestinal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 29: World Historic Review for Gastrointestinal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 30: World 15-Year Perspective for Gastrointestinal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
TABLE 31: World Recent Past, Current & Future Analysis for Gynecologic Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 32: World Historic Review for Gynecologic Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 33: World 15-Year Perspective for Gynecologic Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
TABLE 34: World Recent Past, Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 35: World Historic Review for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 36: World 15-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
TABLE 37: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 38: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 39: World 15-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
III. MARKET ANALYSIS
UNITED STATES
Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
Market Overview
Rising Cancer Cases Spur Growth in Cancer Therapies Market
Estimated Number of New Cancer Cases and Deaths in the US (2019)
Number of Cancer Drugs in Development for the Years 2006, 2009, 2012, 2015 and 2018
Number of FDA-Approved Oncology Drugs in the US (2010-2018)
Cancer Drugs as % of Drug Pipeline in the US for the Period 2010-2019
Patient Assistance Programs Alleviate Cost Burden of Patients to Some Extent
Personalized Medicine Gathers Momentum for Cancer Treatment in the US
A Surging US Prostate Cancer Therapeutics Market
Medicaid Reimbursement Rates for Cancer Treatment with Radiation Indicate Notable Disparity among States
Oncology Care Model to Improve Quality and Reduce Financial Toxicity of Cancer Care
CMS Hikes Reimbursement Rate for CAR-T Therapy
Market Analytics
TABLE 40: USA Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 41: USA Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 42: USA 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
TABLE 43: USA Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 44: USA Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 45: USA 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2021 & 2027
CANADA
Number of New Cancer Cases in Canada: 2019
TABLE 46: Canada Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 47: Canada Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 48: Canada 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
TABLE 49: Canada Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 50: Canada Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 51: Canada 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2021 & 2027
JAPAN
Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
TABLE 52: Japan Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 53: Japan Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 54: Japan 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
TABLE 55: Japan Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 56: Japan Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 57: Japan 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2021 & 2027
CHINA
Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
Cancer Therapies Market: Overview
Number of New Cancer Cases Diagnosed (in Thousands) in China: 2018
Chinese Drug Makers Look to Strengthen Domestic Presence with Low-cost Products
TABLE 58: China Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 59: China Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 60: China 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
TABLE 61: China Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 62: China Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 63: China 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2021 & 2027
EUROPE
Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
Rising Cancer Incidence and New Drug Development Augur Well for European Cancer Therapies Market
Cancer Incidence in Europe: Number of New Cancer Cases (in Thousands) by Site for 2018
Number of New Cancer Cases Diagnosed (in Thousands) in the UK: 2018
TABLE 64: Europe Recent Past, Current & Future Analysis for Cancer Therapies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 65: Europe Historic Review for Cancer Therapies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 66: Europe 15-Year Perspective for Cancer Therapies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2021 & 2027
TABLE 67: Europe Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 68: Europe Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 69: Europe 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
TABLE 70: Europe Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 71: Europe Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 72: Europe 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2021 & 2027
FRANCE
Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
TABLE 73: France Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 74: France Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 75: France 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
TABLE 76: France Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 77: France Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 78: France 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2021 & 2027
GERMANY
Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
TABLE 79: Germany Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 80: Germany Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 81: Germany 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
TABLE 82: Germany Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 83: Germany Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 84: Germany 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2021 & 2027
ITALY
TABLE 85: Italy Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 86: Italy Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 87: Italy 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
TABLE 88: Italy Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 89: Italy Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 90: Italy 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2021 & 2027
UNITED KINGDOM
Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
TABLE 91: UK Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 92: UK Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 93: UK 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
TABLE 94: UK Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 95: UK Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 96: UK 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2021 & 2027
SPAIN
TABLE 97: Spain Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 98: Spain Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 99: Spain 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
TABLE 100: Spain Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 101: Spain Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 102: Spain 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2021 & 2027
RUSSIA
TABLE 103: Russia Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 104: Russia Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 105: Russia 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
TABLE 106: Russia Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 107: Russia Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 108: Russia 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2021 & 2027
REST OF EUROPE
TABLE 109: Rest of Europe Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 110: Rest of Europe Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 111: Rest of Europe 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
TABLE 112: Rest of Europe Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 113: Rest of Europe Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 114: Rest of Europe 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2021 & 2027
ASIA-PACIFIC
Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
An Insight into Asia-Pacific Market for Cancer Therapies
Cancer Incidence in Asia: Number of New Cancer Cases (in Thousands) for 2019
TABLE 115: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Therapies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 116: Asia-Pacific Historic Review for Cancer Therapies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 117: Asia-Pacific 15-Year Perspective for Cancer Therapies by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2021 & 2027
TABLE 118: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 119: Asia-Pacific Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 120: Asia-Pacific 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
TABLE 121: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 122: Asia-Pacific Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 123: Asia-Pacific 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2021 & 2027
AUSTRALIA
Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2022 (E)
TABLE 124: Australia Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 125: Australia Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 126: Australia 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
TABLE 127: Australia Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 128: Australia Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 129: Australia 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2021 & 2027
INDIA
Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2022 (E)
TABLE 130: India Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 131: India Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 132: India 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
TABLE 133: India Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 134: India Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 135: India 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2021 & 2027
SOUTH KOREA
TABLE 136: South Korea Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 137: South Korea Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 138: South Korea 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
TABLE 139: South Korea Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 140: South Korea Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 141: South Korea 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2021 & 2027
REST OF ASIA-PACIFIC
TABLE 142: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 143: Rest of Asia-Pacific Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 144: Rest of Asia-Pacific 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
TABLE 145: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 146: Rest of Asia-Pacific Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 147: Rest of Asia-Pacific 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2021 & 2027
LATIN AMERICA
Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2022 (E)
TABLE 148: Latin America Recent Past, Current & Future Analysis for Cancer Therapies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 149: Latin America Historic Review for Cancer Therapies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 150: Latin America 15-Year Perspective for Cancer Therapies by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2021 & 2027
TABLE 151: Latin America Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 152: Latin America Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 153: Latin America 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
TABLE 154: Latin America Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 155: Latin America Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 156: Latin America 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2021 & 2027
ARGENTINA
TABLE 157: Argentina Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 158: Argentina Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 159: Argentina 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
TABLE 160: Argentina Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 161: Argentina Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 162: Argentina 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2021 & 2027
BRAZIL
TABLE 163: Brazil Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 164: Brazil Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 165: Brazil 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
TABLE 166: Brazil Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 167: Brazil Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 168: Brazil 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2021 & 2027
MEXICO
TABLE 169: Mexico Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 170: Mexico Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 171: Mexico 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
TABLE 172: Mexico Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 173: Mexico Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 174: Mexico 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2021 & 2027
REST OF LATIN AMERICA
TABLE 175: Rest of Latin America Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 176: Rest of Latin America Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 177: Rest of Latin America 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
TABLE 178: Rest of Latin America Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 179: Rest of Latin America Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 180: Rest of Latin America 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2021 & 2027
MIDDLE EAST
Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2022 (E)
TABLE 181: Middle East Recent Past, Current & Future Analysis for Cancer Therapies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 182: Middle East Historic Review for Cancer Therapies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 183: Middle East 15-Year Perspective for Cancer Therapies by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2021 & 2027
TABLE 184: Middle East Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 185: Middle East Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 186: Middle East 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
TABLE 187: Middle East Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 188: Middle East Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 189: Middle East 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2021 & 2027
IRAN
TABLE 190: Iran Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 191: Iran Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 192: Iran 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
TABLE 193: Iran Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 194: Iran Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 195: Iran 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2021 & 2027
ISRAEL
TABLE 196: Israel Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 197: Israel Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 198: Israel 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
TABLE 199: Israel Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 200: Israel Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 201: Israel 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2021 & 2027
SAUDI ARABIA
TABLE 202: Saudi Arabia Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 203: Saudi Arabia Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 204: Saudi Arabia 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
TABLE 205: Saudi Arabia Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 206: Saudi Arabia Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 207: Saudi Arabia 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2021 & 2027
UNITED ARAB EMIRATES
TABLE 208: UAE Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 209: UAE Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 210: UAE 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
TABLE 211: UAE Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 212: UAE Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 213: UAE 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2021 & 2027
REST OF MIDDLE EAST
TABLE 214: Rest of Middle East Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 215: Rest of Middle East Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 216: Rest of Middle East 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
TABLE 217: Rest of Middle East Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 218: Rest of Middle East Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 219: Rest of Middle East 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2021 & 2027
AFRICA
Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2022 (E)
TABLE 220: Africa Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 221: Africa Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 222: Africa 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
TABLE 223: Africa Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 224: Africa Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 225: Africa 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2021 & 2027
IV. COMPETITION
Total Companies Profiled: 80

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings